Volume 35, Issue 1, March 2024

Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2024;35(1):179-83
New-Onset MDA-5 Dermatomyositis in a Patient Following COVID-19 Vaccination: A Case Report
Authors Information

1Department of Rheumatology, 417 Army Share Fund Hospital (NIMTS), Athens, Greece

2Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece

E Bolla, GE Fragoulis, A Iliopoulos

  1. Papagoras C, Fragoulis GE, Zioga N, Simopoulou T, Deftereou K, Kalavri E, et al. Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis 2022 Jul;81(7):1013–6. doi: 10.1136/annrheumdis-2021-221539
  2. Safary A, Esalatmanesh K, Eftekharsadat AT, Jafari Nakjavani MR, Khabbazi A. Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination. Int Immunopharmacol 2022 Sep;110:109061. doi: 10.1016/j.intimp.2022.109061
  3. Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers 2021 Dec 2;7(1):86. doi: 10.1038/s41572-021-00321-x
  4. Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology Guidance for COVID ‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5. Arthritis Rheum [Internet]. 2023 Jan [cited 2024 Jan 21];75(1). Available from: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.42372
  5. Landewé RB, Kroon FP, Alunno A, Najm A, Bijlsma JW, Burmester G-RR, et al. Eular recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-COV-2: The November 2021 update. Ann Rheum Dis 2022;81(12):1628–39. doi:10.1136/annrheumdis-2021-222006
  6. Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis 2022 May;81(5):695–709. doi: 10.1136/annrheumdis-2021-221490
  7. Holzer MT, Krusche M, Ruffer N, Haberstock H, Stephan M, Huber TB, et al. New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. Rheumatol Int 2022 Dec;42(12):2267–76. doi: 10.1007/s00296-022-05176-3
  8. Wang G, Wang Q, Wang Y, Liu C, Wang L, Chen H, et al. Presence of Anti-MDA5 Antibody and Its Value for the Clinical Assessment in Patients With COVID-19: A Retrospective Cohort Study. Front Immunol 2021 Dec 20;12:791348. doi: 10.3389/fimmu.2021.791348
  9. Gonzalez D, Gupta L, Murthy V, Gonzalez EB, Williamson KA, Makol A, et al. Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review. Rheumatol Int 2022 Sep;42(9):1629–41. doi: 10.1007/s00296-022-05149-6
  10. Kitajima T, Funauchi A, Nakajima T, Marumo S, Imura Y, Fukui M. Antimelanoma Differentiation-Associated Gene 5 Antibody–Positive Interstitial Lung Disease After Vaccination With COVID-19 mRNA Vaccines. J Rheumatol 2022 Oct;49(10):1158–62. doi: 10.3899/jrheum.220259
  11. Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 2011 Nov;31(11):1409–17. doi: 10.1007/s00296-011-1999-3